PMID- 8401918
OWN - NLM
STAT- MEDLINE
DCOM- 19931102
LR  - 20190512
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 109
IP  - 4
DP  - 1993 Aug
TI  - Modulation of opioid antinociception by CCK at the supraspinal level: evidence of 
      regulatory mechanisms between CCK and enkephalin systems in the control of pain.
PG  - 1064-70
AB  - 1. Much evidence in the literature supports the idea that cholecystokinin (CCK) 
      interacts with opioids in pain mechanisms. In this work, we have investigated the 
      supraspinal interactions between enkephalins and CCK, using the hot plate test in 
      mice. 2. Intracerebroventricular (i.c.v.) administration of BDNL (a mixed 
      CCKA/CCKB agonist) induced dose-dependent antinociceptive responses on both paw 
      lick and jump responses. In contrast, using the same test, the i.c.v. injection 
      of BC 264 (a selective CCKB agonist) induced a hyperalgesic effect, which was 
      restricted to paw licking and occurred only at a high dose of 2.5 nmol. 3. In 
      addition, i.c.v. administration of BDNL potentiated the antinociceptive effects 
      of the mixed inhibitor of enkephalin degrading enzymes, RB 101 and of the 
      mu-agonist, DAMGO, while BC 264 reduced these effects. 4. Furthermore, at a dose 
      where it interacts selectively with delta-opioid receptors, the opioid agonist 
      BUBU reversed the hyperalgesic responses of BC 264 (2.5 nmol) but was unable to 
      modify the effects induced by BDNL. 5. Taken together, these results suggest the 
      existence of regulatory mechanisms between CCK and enkephalin systems in the 
      control of pain. These regulatory loops could enhance the antinociceptive effects 
      of morphine allowing the opiate doses used to be reduced and thus, possibly, the 
      side-effects to be minimized.
FAU - Noble, F
AU  - Noble F
AD  - Departement de Pharmacochimie Moleculaire et Structurale, U266 INSERM-URA D1500 
      CNRS, Universite Rene Descartes, UFR des Sciences Pharmaceutiques et Biologiques, 
      Paris, France.
FAU - Derrien, M
AU  - Derrien M
FAU - Roques, B P
AU  - Roques BP
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Analgesics)
RN  - 0 (BC 264)
RN  - 0 (Disulfides)
RN  - 0 (Endorphins)
RN  - 0 (Enkephalins)
RN  - 0 (Oligopeptides)
RN  - 0 (Peptide Fragments)
RN  - 100929-53-1 (Enkephalin, Ala(2)-MePhe(4)-Gly(5)-)
RN  - 111035-57-5 
      (tyrosyl-seryl(O-t-butyl)-glycyl-phenylalanyl-leucyl-threonine(O-t-butyl))
RN  - 135949-60-9 (RB 101)
RN  - 47E5O17Y3R (Phenylalanine)
RN  - 9011-97-6 (Cholecystokinin)
RN  - 98640-66-5 (cholecystokinin (27-33), tert-butyloxycarbonyl-Nle(28,31)-)
RN  - M03GIQ7Z6P (Sincalide)
SB  - IM
MH  - Amino Acid Sequence
MH  - Analgesics/*pharmacology
MH  - Animals
MH  - Cholecystokinin/analogs & derivatives/antagonists & 
      inhibitors/*pharmacology/physiology
MH  - Disulfides/pharmacology
MH  - Endorphins/antagonists & inhibitors/*pharmacology
MH  - Enkephalin, Ala(2)-MePhe(4)-Gly(5)-
MH  - Enkephalins/pharmacology/*physiology
MH  - Injections, Intraventricular
MH  - Male
MH  - Mice
MH  - Molecular Sequence Data
MH  - Oligopeptides/pharmacology
MH  - Pain/*physiopathology
MH  - Pain Measurement/drug effects
MH  - Peptide Fragments/antagonists & inhibitors/pharmacology
MH  - Phenylalanine/analogs & derivatives/pharmacology
MH  - Sincalide/analogs & derivatives/pharmacology
MH  - Spinal Cord/*drug effects
PMC - PMC2175722
EDAT- 1993/08/01 00:00
MHDA- 1993/08/01 00:01
PMCR- 1994/08/01
CRDT- 1993/08/01 00:00
PHST- 1993/08/01 00:00 [pubmed]
PHST- 1993/08/01 00:01 [medline]
PHST- 1993/08/01 00:00 [entrez]
PHST- 1994/08/01 00:00 [pmc-release]
AID - 10.1111/j.1476-5381.1993.tb13730.x [doi]
PST - ppublish
SO  - Br J Pharmacol. 1993 Aug;109(4):1064-70. doi: 10.1111/j.1476-5381.1993.tb13730.x.